BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DB959: Additional Phase I data

Additional data from a double-blind, dose-escalation U.S. Phase I trial in 76 healthy volunteers showed that the maximum tolerated dose of DB959 was not reached. The highest dose tested in the trial was 200 mg, which the company said was...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >